Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL9786202 | 0.90 | TDP1 (0.37) | TDP1TSHR | |
| Propylene Glycol SCHEMBL412140 | 0.88 | TDP1 (0.59) | ALDH1A1LMNATDP1TSHR | |
| Propylene Glycol SCHEMBL17272918 | 0.88 | TDP1 (0.59) | ALDH1A1LMNATDP1TSHR | |
| Propylene Glycol SCHEMBL5191636 | 0.88 | TDP1 (0.59) | ALDH1A1LMNATDP1TSHR | |
| Ethylene Glycol SCHEMBL3197361 | 0.86 | TSHR (0.46) | ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL3200076 | 0.86 | TSHR (0.46) | ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL3171689 | 0.86 | TSHR (0.46) | ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL9756248 | 0.86 | TSHR (0.46) | ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL622577 | 0.86 | TSHR (0.46) | ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL5830392 | 0.86 | TSHR (0.46) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626950-A4 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7186863-B2 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1626950-A1 | SERTRALINE COMPOSITIONS | Transform Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050014829-A1 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2005000786-A1 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014829-A1 | Sertraline compositions | SUCNR1, TST, SORD | ALDH1A1 1465/4885LMNA 2403/4885TDP1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.